Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Equity Average (2021 - 2025)

Historic Equity Average for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $983.5 million.

  • Janux Therapeutics' Equity Average rose 4972.59% to $983.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $983.5 million, marking a year-over-year increase of 4972.59%. This contributed to the annual value of $683.6 million for FY2024, which is 10555.59% up from last year.
  • Janux Therapeutics' Equity Average amounted to $983.5 million in Q3 2025, which was up 4972.59% from $1.0 billion recorded in Q2 2025.
  • Janux Therapeutics' 5-year Equity Average high stood at $1.0 billion for Q1 2025, and its period low was $305.4 million during Q2 2023.
  • In the last 5 years, Janux Therapeutics' Equity Average had a median value of $371.5 million in 2021 and averaged $533.8 million.
  • Its Equity Average has fluctuated over the past 5 years, first crashed by 1273.95% in 2023, then surged by 14215.96% in 2024.
  • Over the past 5 years, Janux Therapeutics' Equity Average (Quarter) stood at $371.5 million in 2021, then fell by 12.22% to $326.1 million in 2022, then rose by 6.29% to $346.6 million in 2023, then skyrocketed by 142.16% to $839.4 million in 2024, then increased by 17.17% to $983.5 million in 2025.
  • Its Equity Average was $983.5 million in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.0 billion in Q1 2025.